v3.25.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Shares reserved under the Sales Agreement
Common Stock
Common Stock
Shares reserved under the Sales Agreement
Additional Paid-in Capital
Additional Paid-in Capital
Shares reserved under the Sales Agreement
Treasury Stock
Accumulated Deficit
AOCI Attributable to Parent
Beginning balance (in shares) at Mar. 31, 2023     7,315,583            
Beginning balance at Mar. 31, 2023 $ 12,080   $ 7   $ 342,893   $ (3,968) $ (326,852) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 2,182       2,182        
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)     4,843            
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan 8       8        
Issuance of common stock under Open Market Sale Agreement, net of issuance costs (in shares)       4,698,495          
Issuance of common stock under Open Market Sale Agreement, net of issuance costs   $ 35,899   $ 5   $ 35,894      
Issuance of common stock and pre-funded warrants through public offering, net of issuance costs (in shares)     15,010,810            
Issuance of common stock upon exercise of Pre-Funded Warrants 93,479   $ 15   93,464        
Net loss (29,362)             (29,362)  
Ending balance (in shares) at Mar. 31, 2024     27,029,731            
Ending balance at Mar. 31, 2024 114,286   $ 27   474,441   (3,968) (356,214) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 4,315       4,315        
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)     74,804            
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan 201       201        
Issuance of common stock under Open Market Sale Agreement, net of issuance costs (in shares)     1,108,587            
Issuance of common stock under Open Market Sale Agreement, net of issuance costs 3,000   $ 1   2,999        
Unrealized gain on marketable securities available-for-sale, net $ 5               5
Issuance of common stock and pre-funded warrants through public offering, net of issuance costs (in shares) 788,359                
Issuance of common stock upon exercise of Pre-Funded Warrants $ 1   $ 1            
Net loss (51,418)             (51,418)  
Ending balance (in shares) at Mar. 31, 2025     29,001,481            
Ending balance at Mar. 31, 2025 $ 70,390   $ 29   $ 481,956   $ (3,968) $ (407,632) $ 5